Royalty Pharma plc Class A

XNASHealth care

Last traded price · USD

$67.57

+1.76%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 04:13 IST · A quote does not mean the product is available to trade on your account.

Day's open: $65.65
Previous close: $66.40
Volume: 3.8M
Day's high: $67.66
Day's low: $64.84

In brief

Royalty Pharma plc is a health care company listed on Nasdaq, valued at about $30.09B.
Its shares closed at $67.56 on 4 Nov 2026, up 78.5% over the past year.
From India you can buy RPRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Royalty Pharma plc (RPRX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole RPRX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade RPRX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

0.2% below its 52-week high
Closed at $67.56 on 4 Nov 2026: 0.2% below the 52-week high of $67.71 (30 Oct 2026) and 81.1% above the low of $37.31 (24 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +19.7% (SPY −1.6%, XLV +13.5%). 3 months: +17.0% (SPY −0.4%, XLV +15.5%). 1 year: +78.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RPRX, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $67.56 was 11.5% above its 50-day average ($60.59) and 26.0% above its 200-day average ($53.63). It has closed above the 200-day for 457 sessions, since 10 Jan 2025. The 50-day average crossed above the 200-day on 4 Feb 2025, 440 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Next ex-dividend date: 13 Nov 2026
$0.235 a share, payable 10 Dec 2026; unchanged from the previous payment (ex-date 14 Aug 2026).
Corporate actions record · as of 5 Nov 2026
RSI(14) at 74.4, 70 or above
The 14-session relative strength index closed at 74.4 on 4 Nov 2026, its 10th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+19.7%

6 months+33.2%

1 year+78.5%

5 years+70.7%

Newswire

About

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Website

Notable moves

November 5, 2025
+6.82%
January 10, 2025
+12.56%
February 6, 2024
+8.95%

Royalty Pharma plc Class A

XNASHealth care

Last traded price · USD

$67.57

+1.76%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 04:13 IST · A quote does not mean the product is available to trade on your account.

Day's open: $65.65
Previous close: $66.40
Volume: 3.8M
Day's high: $67.66
Day's low: $64.84

In brief

Royalty Pharma plc is a health care company listed on Nasdaq, valued at about $30.09B.
Its shares closed at $67.56 on 4 Nov 2026, up 78.5% over the past year.
From India you can buy RPRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Royalty Pharma plc (RPRX) shares from India?

Do I need the price of a whole RPRX share to invest?

How much can I invest in US stocks in a year?

Can I trade RPRX options or futures?

Insights

Quotes run fifteen minutes behind.

0.2% below its 52-week high
Closed at $67.56 on 4 Nov 2026: 0.2% below the 52-week high of $67.71 (30 Oct 2026) and 81.1% above the low of $37.31 (24 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +19.7% (SPY −1.6%, XLV +13.5%). 3 months: +17.0% (SPY −0.4%, XLV +15.5%). 1 year: +78.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RPRX, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $67.56 was 11.5% above its 50-day average ($60.59) and 26.0% above its 200-day average ($53.63). It has closed above the 200-day for 457 sessions, since 10 Jan 2025. The 50-day average crossed above the 200-day on 4 Feb 2025, 440 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Next ex-dividend date: 13 Nov 2026
$0.235 a share, payable 10 Dec 2026; unchanged from the previous payment (ex-date 14 Aug 2026).
Corporate actions record · as of 5 Nov 2026
RSI(14) at 74.4, 70 or above
The 14-session relative strength index closed at 74.4 on 4 Nov 2026, its 10th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+19.7%

6 months+33.2%

1 year+78.5%

5 years+70.7%

Newswire

About

Website

Notable moves

November 5, 2025
+6.82%
January 10, 2025
+12.56%
February 6, 2024
+8.95%

Royalty Pharma plc Class A

Royalty Pharma plc in brief

0.2% below its 52-week high

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

Next ex-dividend date: 13 Nov 2026

RSI(14) at 74.4, 70 or above

Royalty Pharma plc Class A

Royalty Pharma plc in brief

0.2% below its 52-week high

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

Next ex-dividend date: 13 Nov 2026

RSI(14) at 74.4, 70 or above